Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 2
2012 2
2013 1
2015 2
2017 1
2019 1
2020 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children.
Traver E, Rodríguez-Pascau L, Meya U, Pina G, Pascual S, Poli S, Eckland D, van de Wetering J, Ke A, Lindauer A, Martinell M, Pizcueta P. Traver E, et al. Among authors: lindauer a. CPT Pharmacometrics Syst Pharmacol. 2024 Mar 29. doi: 10.1002/psp4.13132. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38549500 Free article.
Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
Jolling K, Äbelö A, Luyckx N, Nandeuil MA, Govoni M, Cella M, Lindauer A. Jolling K, et al. Among authors: lindauer a. CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):460-468. doi: 10.1002/psp4.12405. Epub 2019 May 11. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31077576 Free PMC article.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, Nock V, Fleury A. Kanacher T, et al. Among authors: lindauer a. Pharmaceutics. 2020 Dec 8;12(12):1191. doi: 10.3390/pharmaceutics12121191. Pharmaceutics. 2020. PMID: 33302490 Free PMC article.
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, Jaehde U; Central European Society for Anticancer Drug Research-EWIV. Lentz F, et al. Among authors: lindauer a. Anticancer Drugs. 2009 Feb;20(2):97-103. doi: 10.1097/CAD.0b013e328322fbc5. Anticancer Drugs. 2009. PMID: 19209025 Clinical Trial.
15 results